Literature DB >> 15505088

Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study.

Winfried März1, Hubert Scharnagl, Karl Winkler, Andreas Tiran, Markus Nauck, Bernhard O Boehm, Bernhard R Winkelmann.   

Abstract

BACKGROUND: Markers of systemic inflammation and LDL cholesterol (LDL-C) have been considered independent risk factors of coronary artery disease (CAD). We examined whether alterations of LDL metabolism not reflected by LDL-C were associated with low-grade inflammation, vascular injury, and CAD. METHODS AND
RESULTS: We studied 739 subjects with stable angiographic CAD and 570 matched control subjects in which CAD had been ruled out by angiography. The association of LDL triglycerides (LDL-TGs) (odds ratio [OR], 1.30; 95% CI, 1.19 to 1.43; P<0.001) with CAD was stronger than that of LDL-C (OR, 1.10; 95% CI, 1.00 to 1.21; P=0.047). The predictive value of LDL-TG for CAD was independent of LDL-C. "Sensitive" C-reactive protein (CRP), serum amyloid A, fibrinogen, interleukin 6, intercellular adhesion molecule-1 (ICAM-1), and vascular adhesion molecule-1 (VCAM-1) increased in parallel to LDL-TG. CRP, ICAM-1, and VCAM-1 were inversely related to LDL-C. To examine whether LDL-TGs were associated with the distribution of LDL subfractions, we studied 114 individuals with impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes mellitus. In subjects with high LDL-TG, LDLs were depleted of cholesteryl esters (CEs), and VLDLs, IDLs, and dense LDLs were significantly elevated.
CONCLUSIONS: Alterations of LDL metabolism characterized by high LDL-TG are related to CAD, systemic low-grade inflammation, and vascular damage. High LDL-TGs are indicative of CE-depleted LDL, elevated IDL, and dense LDL. LDL-TG may better reflect the atherogenic potential of LDL than LDL-C.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15505088     DOI: 10.1161/01.CIR.0000146898.06923.80

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  46 in total

1.  Association between the MARS rs6782181 polymorphism and serum lipid levels.

Authors:  Jian Wu; Rui-Xing Yin; Tao Guo; Quan-Zhen Lin; Guang-Yuan Shi; Jia-Qi Sun; Shao-Wen Shen; Yi-Ming Wang; Hui Li; Jin-Zhen Wu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.

Authors:  John J Albers; April Slee; Jerome L Fleg; Kevin D O'Brien; Santica M Marcovina
Journal:  Atherosclerosis       Date:  2016-06-11       Impact factor: 5.162

3.  New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk.

Authors:  Gerald Klose; Frank Ulrich Beil; Hans Dieplinger; Arnold von Eckardstein; Bernhard Föger; Ioanna Gouni-Berthold; Franz Heigl; Wolfgang Koenig; Gert M Kostner; Ulf Landmesser; Ulrich Laufs; Frank Leistikow; Winfried März; Georg Noll; Klaus G Parhofer; Bernhard Paulweber; Walter F Riesen; Jürgen R Schaefer; Elisabeth Steinhagen-Thiessen; Armin Steinmetz; Hermann Toplak; Christoph Wanner; Eberhard Windler
Journal:  Wien Klin Wochenschr       Date:  2014-03-11       Impact factor: 1.704

4.  Effects of autoimmune antibodies anti-lipoprotein lipase, anti-low density lipoprotein, and anti-oxidized low density lipoprotein on lipid metabolism and atherosclerosis in systemic lupus erythematosus.

Authors:  James Fesmire; Marianne Wolfson-Reichlin; Morris Reichlin
Journal:  Rev Bras Reumatol       Date:  2010 Sep-Oct

5.  Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease.

Authors:  Anum Saeed; Elena V Feofanova; Bing Yu; Wensheng Sun; Salim S Virani; Vijay Nambi; Josef Coresh; Cameron S Guild; Eric Boerwinkle; Christie M Ballantyne; Ron C Hoogeveen
Journal:  J Am Coll Cardiol       Date:  2018-07-10       Impact factor: 24.094

6.  [New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk : Statement of the D•A•CH Society for Prevention of Cardiovascular Diseases, the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society for Cardiology].

Authors:  G Klose; F U Beil; H Dieplinger; A von Eckardstein; B Föger; I Gouni-Berthold; W Koenig; G M Kostner; U Landmesser; U Laufs; F Leistikow; W März; M Merkel; D Müller-Wieland; G Noll; K G Parhofer; B Paulweber; W Riesen; J R Schaefer; E Steinhagen-Thiessen; A Steinmetz; H Toplak; C Wanner; E Windler
Journal:  Internist (Berl)       Date:  2014-05       Impact factor: 0.743

7.  Association of LIPC -250G>A polymorphism and several environmental factors with serum lipid levels in the Guangxi Bai Ku Yao and Han populations.

Authors:  Li Meng; Yin Ruixing; Li Yiyang; Long Xingjiang; Li Kela; Liu Wanying; Zhang Lin; Lin Weixiong; Yang Dezhai; Pan Shangling
Journal:  Lipids Health Dis       Date:  2010-03-11       Impact factor: 3.876

8.  Interactions between rs5498 polymorphism in the ICAM1 gene and traditional risk factors influence susceptibility to coronary artery disease.

Authors:  Beata Sarecka-Hujar; Iwona Zak; Jolanta Krauze
Journal:  Clin Exp Med       Date:  2008-12-02       Impact factor: 3.984

9.  LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study.

Authors:  Günther Silbernagel; Hubert Scharnagl; Marcus E Kleber; Graciela Delgado; Tatjana Stojakovic; Reijo Laaksonen; Jeanette Erdmann; Tuomo Rankinen; Claude Bouchard; Ulf Landmesser; Heribert Schunkert; Winfried März; Tanja B Grammer
Journal:  Atherosclerosis       Date:  2018-12-28       Impact factor: 5.162

10.  Triglyceride to HDL-C ratio and increased arterial stiffness in children, adolescents, and young adults.

Authors:  Elaine M Urbina; Philip R Khoury; Connie E McCoy; Lawrence M Dolan; Stephen R Daniels; Thomas R Kimball
Journal:  Pediatrics       Date:  2013-03-04       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.